EMA Withdrawn: Ribavirin Teva Pharma B.V. (ribavirin) — Teva B.V.

View source ↗

Summary

The EMA withdrew Ribavirin Teva Pharma B.V. (ribavirin) from the market in June 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Viral Hepatitis

Drugs mentioned

• Ribavirin Teva Pharma B.V. (ribavirin)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis C, Chronic. MAH: Teva B.V.. Decision date: 22/06/2021